Clinical Study of Chemotherapy Combined with CIK Cell Immunotherapy for Non-small Cell Lung Cancer

Xiao-biao MA; Feng LUO; Yong-liang GAO; Jing-chao HAO

doi:10.12259/j.issn.2095-610X.S20201215

Volume 41 Issue 12

Dec. 2019

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2020 > 41(12): 60-67

Xiao-biao MA, Feng LUO, Yong-liang GAO, Jing-chao HAO. Clinical Study of Chemotherapy Combined with CIK Cell Immunotherapy for Non-small Cell Lung Cancer[J]. Journal of Kunming Medical University, 2020, 41(12): 60-67. doi: 10.12259/j.issn.2095-610X.S20201215

Citation:

Xiao-biao MA, Feng LUO, Yong-liang GAO, Jing-chao HAO. Clinical Study of Chemotherapy Combined with CIK Cell Immunotherapy for Non-small Cell Lung Cancer[J]. Journal of Kunming Medical University, 2020, 41(12): 60-67. doi: 10.12259/j.issn.2095-610X.S20201215

Citation:

PDF( 683 KB)

Clinical Study of Chemotherapy Combined with CIK Cell Immunotherapy for Non-small Cell Lung Cancer

doi: 10.12259/j.issn.2095-610X.S20201215

1.
Yunnan Cancer Hospital，The 3rd Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650118
2.
School of Pharmaceutical Science，Key Laboratory of Natural Pharmacology of Yunnan Province，Kunming Medical University， Kunming Yunnan 650500，China

Received Date: 2020-04-16
Publish Date: 2020-12-25

Abstract

Abstract

Objective To evaluate the clinical efficacy of chemotherapy combined with CIK （cytokine-induced killer）cell immunotherapy on early and advanced stages non small cell lung cancer （NSCLC）patients. Methods A total of 122 NSCLC patients admitted to the Third Affiliated Hospital of Kunming Medical University from 2013 to 2016, according to the course of disease, the patients divided into early stage （stage I-II）and late stage （stage III-IV）; and were randomly divided into four groups: chemotherapy a group （n = 30）, combined with CIK a group （n = 31）, chemotherapy B group （n = 30）, combined with CIK B group （n = 31）. Among them, gemcitabine combined with cisplatin （GP）was used in all the groups. The clinical efficacy, quality of life and changes of peripheral blood lymphocytes and cytokines were evaluated. Results Compared with the chemotherapy group, the ORR and DCR values were significantly increased （67.74%, 45.16%）and （74.19%, 64.52%）respectively （P < 0.05）, KPS and ECOG scores were significantly increased （80.65%, 58.06%）and （80.65%, 70.97%） respectively （ P < 0.05）, in the combined CIK groups. The ratio of CD3 ⁺, CD8⁺ lymphocytes and CIK cells in patients' peripheral blood was significantly increased （P < 0.05）and the expression level of IFN - γ, TNF - α, IL-4 and IL-6 cytokines in patients' peripheral blood was significantly increased （ P < 0.05）and the survival period of patients was prolonged （ P < 0.05）in the combined CIK groups. Compared with the combined CIK A group （early stage）, the ratio of CD3 ⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ T lymphocytes, NK cell ratio and CIK cell ratio in the peripheral blood of the patients were significantly increased, and the expression levels of IFN - γ, TNF - α, IL-2, IL-4 and IL-6 cytokines in the peripheral blood were maintained and enhanced in the combined CIK B group （advanced stage）（P < 0.05）. Conclusion Chemotherapy combined with CIK cell therapy can significantly improve the clinical efficacy, prolong the survival period, and improve the short-term quality of life of NSCLC patients in different stages, and significantly improve the ability of immune cells in vivo to continuously resist tumor cytotoxicity and immune response, especially for patients in advanced stage.
- CIK cell immunotherapy,
- Non-small cell lung cancer,
- Chemotherapy,
- Combined therapy

FullText(HTML)

References(20)

References

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2018, 68（6）: 394-424. doi: 10.3322/caac.21492
[2]	佚名. 2018年全国最新癌症报告: 每分钟有7人被确诊为癌症[J], 新民周刊, 2018, 5（14）: 53～54.
[3]	Jemal A, Siegel R, Ward E, et al. Cancer statistics[J]. CA Cancer J Clin. 2007, 57（1）: 43-66. doi: 10.3322/canjclin.57.1.43
[4]	Black R C, Khurshid H. NSCLC: an update of driver mutations, their role in pathogenesis and clinical significance[J]. Rhode Island Med J. 2015, 98（10）: 25-28.
[5]	Williams M, Liu Z W, Hunter A, et al. An updated systematic review of lung chemo - radiotherapy using a new evidence aggregation method[J]. Lung Cancer. 2015, 87（3）: 290-295. doi: 10.1016/j.lungcan.2014.12.004
[6]	Verma R, Foster R E, Horgan K, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer[J]. Breast Cancer Res. 2016, 18（1）: 10. doi: 10.1186/s13058-015-0669-x
[7]	戴秀梅, 魏卫, 袁保兰. 吉非替尼治疗前后肺腺癌患者外周血T淋巴细胞亚群检测的临床意义[J]. 中国实用医刊, 2012, 39（12）: 91-92. doi: 10.3760/cma.j.issn.1674-4756.2012.08.044
[8]	Chen D, Sha H H, Hu T M, et al. Cytokine-induced killer cells as a feasible adoptive immunotherapy for the treatment of lung cancer[J]. Cell Death and Disease, 2018, 9（3）: 366. doi: 10.1038/s41419-018-0404-5
[9]	张志强, 马怡, 劣迹艺人, 等. 实体肿瘤治疗效果评价标准的研究进展[J]. 中国临床实用医学, 2019, 10（2）: 71-73.
[10]	Khanna P, Blais N, Gaudreau P O, et al. Immunotherapy comes of age in lung cancer[J]. Clinical Lung Cancer, 2017, 18（1）: 13-22. doi: 10.1016/j.cllc.2016.06.006
[11]	Zhu J, Li R, Tiselius E, et al. Immunotherapy （Excluding checkpoint inhibitors） for stage I to III non - small cell lung cancer treated with surgery or radiotherapy with curative intent[J]. Cochrane Database of Systematic Reviews, 2017, 12（12）: CD011300.
[12]	Zhang J, Zhu L, Du H, et al. Autologous cytokine - induced killer cell therapy in lung cancer patients: a retrospective study[J]. Biomed Pharmacother, 2015, 70: 248-252. doi: 10.1016/j.biopha.2014.12.025
[13]	Shapouri M A, Mohammadian S, Vazini H, et al. Macrophage plasticity, polarization, and function in health and disease[J]. Journal of Cellular Physiology, 2018, 233（9）: 6425-6440. doi: 10.1002/jcp.26429
[14]	Shang N, Figini M, Shangguan J, et al. Dendritic cells based immunotherapy[J]. American Journal of Cancer Research, 2017, 7（10）: 2091-2102.
[15]	Staedtke V, Bai R Y, Kim K, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome[J]. Nature. 2018, 564（7735）: 273-277.
[16]	Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med. 2018, 24（6）: 739-748. doi: 10.1038/s41591-018-0036-4
[17]	Zhang L, Wang J, Wei F, et al. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients[J]. Oncotarget. 2016, 7（28）: 43604-43615. doi: 10.18632/oncotarget.9871
[18]	Li D, Li C, Zhang K X, et al. CIK may enhance the lethal effect of cisplatin on the lung adenocarcinoma cell line A549[J]. Chin J Clin Lab Sci, 2013, 31（12）: 915-918.
[19]	Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients[J]. Tumor Biology, 2014, 35（2）: 987-994. doi: 10.1007/s13277-013-1132-1
[20]	Zhang L, Xu Y, Shen J, et al. Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer[J]. Radiation Oncology, 2016, 11（1）: 1-8. doi: 10.1186/s13014-015-0579-1

Relative Articles(20)

Relative Articles

[1]	Shengxi YANG, Jiade ZHU, Qiurui LI, Wenlian TU. Clinical Study of Aumolertinib Versus Osimertinib in the Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Journal of Kunming Medical University, 2025, 46(5): 1-7.
[2]	Chao HONG, Xudong XIANG, Yingfu LI, Yang CAO, Xueya CHEN, Shuai LI, Anhao XING, Mu LIN, Qianli MA. Association of Polymorphisms in the 3' UTR of Genes in the ERK1/2 Signaling Pathway with Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2024, 45(3): 7-17. doi: 10.12259/j.issn.2095-610X.S20240302
[3]	Huimin YU, Xin XIN, Zhiwei LIANG. Predictive Value of KIAA1199 and Linc00673 Genes on Chemotherapy Efficacy in Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2024, 46(): 1-6.
[4]	Caini ZHANG, Ya LI. A Meta-analysis of the Efficacy and Safety of Camrelizumab Combined with Chemotherapy in the Treatment of Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2024, 45(6): 75-84. doi: 10.12259/j.issn.2095-610X.S20240610
[5]	Yan LIANG, Lei WANG, Ming LEI, Benchao CHEN, Ping SUN, Shuai LI, Li LIU, Qianrong WANG, Manlin LIAO, Qianli MA. Correlation between KRAS Gene Polymorphism and Non-small Cell Lung Cancer in Yunnan Han Population. Journal of Kunming Medical University, 2023, 44(2): 52-60. doi: 10.12259/j.issn.2095-610X.S20230210
[6]	Chuntao LI, Xuemei ZHANG, Yandi SU, Jianqing Zhang. Construction of Stable Transfected Cell Line A549 of Non-small Cell Lung Cancer by Overexpressing and Knocking Down LncRNA RP11-521C20.3. Journal of Kunming Medical University, 2023, 44(10): 1-9. doi: 10.12259/j.issn.2095-610X.S20231016
[7]	Jia YANG, Ya-xian LI, Ying-ying WANG, Lin XIAO, Chuan-yin LI, Fang TAN, Qian-li MA, Shu-yuan LIU. Association of the miR-149,miR-219 and miR-let-7 Polymorphisms with the Occurrence and Development of Non-small Cell Lung Cancer in a Chinese Han Population in Yunnan Province. Journal of Kunming Medical University, 2021, 42(10): 22-28. doi: 10.12259/j.issn.2095-610X.S20211037
[8]	Ying-xia WANG, Qin HE, Guo-fang WANG, Xuan ZHANG. Expression and Significance of microRNA-21 and EGFR in Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2021, 42(8): 101-105. doi: 10.12259/j.issn.2095-610X.S20210818
[9]	Wang Juan , Su Guo Miao , Pan Guo Qing , Bian Li , Yang Zhe , Zeng Ding Tao . . Journal of Kunming Medical University, 2020, 41(09): 1-6.
[10]	Tang Shi Cong , Pan Hong , Huang Yao Yuan , Zhou Xin , Wang Shou Feng , Zuo Chuan Tian , Mao Nai Quan . . Journal of Kunming Medical University, 2017, 38(02): 28-32.
[11]	Cao Lan . Curative Effect of Multimode Combined Treatment of Ultrapulsed CO2 Laser on Facial Atrophic Acne Scars. Journal of Kunming Medical University,
[12]	Qiu Hong Mei . . Journal of Kunming Medical University,
[13]	Gao Ran . . Journal of Kunming Medical University,
[14]	Wang Ruo Tian . . Journal of Kunming Medical University,
[15]	Zhou JieYan . . Journal of Kunming Medical University,
[16]	Yang Yong Rui . . Journal of Kunming Medical University,
[17]	. Thoracoscopic Lobectomy in the Treatment of 54 Patients with Non-small Cell Lung Cancer. Journal of Kunming Medical University,
[18]	Fan Qiong . . Journal of Kunming Medical University,
[19]	Yang Fang . . Journal of Kunming Medical University,
[20]	Zhang Lan Feng . . Journal of Kunming Medical University,